OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
09 Novembre 2020 - 07:30AM
OXURION NV Confirms New Patents for THR-687 Issued by European and
US Patent Offices
OXURION NV Confirms New Patents for
THR-687 Issued by European and US Patent Offices
Composition-of-matter patents protect
THR-687 until 2039-2044
Leuven, Belgium and Boston, MA, November
9, 2020 – 7.30 AM CET – Oxurion NV (Euronext Brussels:
OXUR), a biopharmaceutical company developing potential next
generation standard-of-care therapies to better preserve the vision
of patients with diabetic macular edema (DME), today announces a
further strengthening of its intellectual property (IP) portfolio
governing THR-687, an integrin antagonist being developed for the
treatment of DME.
The European Patent Office (EPO) and the United
States Patent and Trademark Office (USPTO) have both issued new
composition-of-matter patents covering THR-687. Patents EP3613739
and US10703752 were issued in November 2020 and July 2020
respectively, and expire in 2039, with possible patent extensions
of up to 5 additional years (2044). An international application is
still pending.
THR-687 is a potential best-in-class small
molecule pan-RGD integrin antagonist being developed to treat DME
holding potential of becoming the standard of care for DME
patients.
Data from a Phase 1 trial showed that THR-687 is
well-tolerated and safe with no dose-limiting toxicities and no
serious adverse events reported at any of the doses evaluated in
the study. Early signs of efficacy were also observed across all
doses, with a rapid onset of action in mean Best Corrected Visual
Acuity (BCVA) from Day 1. Following a single injection of the
highest dose of THR-687, this activity was maintained at Month 3
with a mean BCVA improvement of 12.5 letters.
Oxurion pre-clinical data show that THR-687 has
the potential to be developed for additional significant
indications, including wet Age-related Macular Degeneration (wAMD)
and Retinal Vein Occlusion (RVO).
Patrik De Haes, M.D., CEO of
Oxurion, said: “We are delighted that by using our
in-house expertise to chemically optimize THR-687, we have
generated an improved molecule for clinical development and
extended its composition-of-matter patent coverage. The new patents
that have been granted will ensure exclusivity until at least 2039
in the most important US and European markets for THR-687. These
patents are a key element in securing the potentially significant
commercial opportunity for THR-687, given our initial aim to make
it the standard of care for all DME patients.”
END
For further information please contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/ Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing potential next generation
standard of care therapies to better preserve vision in patients
with diabetic macular edema (DME), the leading cause of vision loss
in diabetic patients worldwide.
Oxurion is building a leading global franchise
in the treatment of DME, based on the successful development of its
two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being developed as a
potential new standard of care for DME patients who respond
sub-optimally to anti-VEGF therapy. THR-149 has shown positive
topline Phase 1 results for the treatment of DME. The Company
is currently conducting a Phase 2 clinical trial evaluating THR-149
with DME-patients who previously responded sub-optimally to
anti-VEGF therapy. THR-149 was developed in conjunction with
Bicycle Therapeutics PLC (NASDAQ: BCYC).
- THR-687, a pan-RGD integrin inhibitor, initially being
developed as a potential new standard of care for DME patients.
Positive topline results in a Phase 1 clinical study assessing it
as a treatment for DME were announced in January 2020. THR-687 is
expected to enter a Phase 2 clinical trial by mid-2021.
THR-687 is an optimized compound derived from a broader
library of integrin inhibitors in-licensed from Galapagos NV
(Euronext & NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol
OXUR.
More information is available at
www.oxurion.com.
Important information about
forward-looking statementsCertain statements in this press
release may be considered “forward-looking”. Such forward-looking
statements are based on current expectations, and, accordingly,
entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such
forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or any other
reason. Additional information concerning risks and uncertainties
affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is
contained in the Company’s Annual Report. This press release does
not constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2023 a Mar 2024